Corporate Member Takeda - NEW Indication

Corporate Member Takeda - NEW Indication

ALUNBRIG (brigatinib)
June, 2017

Takeda Oncology is proud to announce the FDA approval of ALUNBRIG (brigatinib), a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members